Thyrocare Technologies Limited reported a consolidated net profit of ₹51.33 crore for the quarter ended June 30, 2026, marking a 34% year-on-year increase from ₹38.28 crore in Q1FY25. The diagnostic services provider saw its total income from operations rise 24% to ₹244.17 crore, up from ₹197.68 crore in the corresponding period last year, reflecting robust demand across its testing portfolio.

The results were approved by the Board of Directors on July 23, 2026, and disclosed under Regulation 30 and 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company published the unaudited financial results in Navshakti and Business Standard newspapers, with full details available on its investor website.

On a standalone basis, Thyrocare Technologies recorded a net profit of ₹50.17 crore, a 39% jump from ₹36.05 crore in Q1FY25. Revenue from operations stood at ₹229.17 crore, compared to ₹182.85 crore in the previous year’s quarter. The growth trajectory continued from Q4FY25, where consolidated revenue was ₹228.26 crore and net profit was ₹48.70 crore.

The company’s equity share capital increased significantly during FY25, rising from ₹52.99 crore at the end of Q1FY25 to ₹159.17 crore by March 31, 2026, and remaining stable through Q1FY26. This capital expansion supports the company’s ongoing network growth and capacity enhancements.

What the Numbers Show

The divergence between revenue growth (24%) and net profit growth (34%) indicates improving operating leverage in the quarter. While both consolidated and standalone metrics showed strong double-digit growth, the slightly higher standalone profit margin suggests efficient cost management at the corporate level. The consistent rise in earnings per share, despite the significant dilution from increased share capital earlier in the fiscal year, underscores the underlying strength of the business model.

Thyrocare Technologies has made the audio recording of its post-results earnings conference call publicly available, providing investors with direct access to management’s commentary on its latest financial performance. The call was held on July 23, 2026, at 6:00 PM IST, focusing on the company’s unaudited financial results for the quarter ended June 30, 2026. This disclosure ensures transparency and allows stakeholders to review the detailed discussion regarding operational metrics and financial outcomes for Q4FY27.

The release of the audio recording is in compliance with Regulation 30(6) read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Thyrocare Technologies Limited submitted this disclosure to both the National Stock Exchange of India Limited and BSE Limited, ensuring adherence to mandatory reporting standards for listed entities in India.

Key Details of the Earnings Call

The conference call was conducted with analysts and investors to discuss the financial health and strategic direction of the company following the closure of the fiscal year. While the full transcript is yet to be shared, the audio recording provides immediate access to the verbal disclosures made by the company’s leadership team.

Availability and Next Steps

Investors and analysts can access the audio recording directly through the company’s investor relations portal at https://investor.thyrocare.com/financials/quarterly-financial-results/ . The company has indicated that a written transcript of the proceedings will be shared shortly after the initial release of the audio file. This sequential disclosure process allows for immediate auditory review while preparing a comprehensive textual record for archival and reference purposes.

Regulatory Compliance

The disclosure was authorized by Brijesh Kumar, Company Secretary and Compliance Officer of Thyrocare Technologies Limited. The submission underscores the company’s commitment to regulatory compliance under the SEBI Listing Regulations, ensuring that all material information regarding financial results is disseminated fairly and promptly to all market participants. The reference to the previous letter dated July 16, 2026, confirms the continuity of the disclosure timeline associated with the quarterly results announcement.